Glucose oxidase - Karo Pharma

Drug Profile

Glucose oxidase - Karo Pharma

Alternative Names: Glucose oxidase and glucose -Karo Pharma; T268A cold spray

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tanomed; Umea University
  • Developer Karo Pharma AB
  • Class Antivirals; Glucose oxidases
  • Mechanism of Action Immunomodulators; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Common cold

Most Recent Events

  • 04 Aug 2017 Phase II development is ongoing for Common cold (In infants, In children, In adults) in Sweden (Karo Pharma website, August 2017)
  • 01 Jan 2013 Phase-II clinical trials in Common cold (In adults) in Sweden (Intranasal) (NCT01883440, NCT01883453)
  • 01 Oct 2012 Phase-II clinical trials in Common cold (In infants, In children) in Sweden (Intranasal) (NCT01883427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top